Leef Brands (LEEEF) Invested Capital (2024 - 2026)

Leef Brands (LEEEF) reported Invested Capital of $105000.0 for Q1 2026, down 69.12% sequentially from $340000.0 in Q4 2025.

Leef Brands (LEEEF) Invested Capital (2024 - 2026) Analysis & Trends

Leef Brands (LEEEF) has 3 years of Invested Capital data on file, last reported at $105000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Invested Capital changed N/A year-over-year to $105000.0; the trailing twelve-month figure through Mar 2026 stood at $945000.0 (changed N/A YoY), and the FY2025 full-year result was $340000.0, down 32.0% from the prior year.
  • Invested Capital fell to $105000.0 in Q1 2026, from $340000.0 in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $500000.0 in Q4 2024 to a low of $105000.0 in Q1 2026.
  • A 3-year average of $315000.0 and a median of $340000.0 in 2025 frame the typical range for Invested Capital.
  • Peak annual rise in Invested Capital reached 32.0% in 2025, while the deepest fall reached 32.0% in 2025.
  • Tracing LEEEF's Invested Capital over 3 years: stood at $500000.0 in 2024, then tumbled by 32.0% to $340000.0 in 2025, then plunged by 69.12% to $105000.0 in 2026.
  • Business Quant data shows LEEEF's Invested Capital at $105000.0 in Q1 2026, $340000.0 in Q4 2025, and $500000.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Invested Cap. (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 1.11 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 2.61 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 31.13 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - 7.15 Bn
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 1.93 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 73.00 Mn
10 Leef Brands 51.94 Mn 46.18 Mn 4.62 Mn 105,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 105,000.00
Dec 31, 2025 340,000.00
Dec 31, 2024 500,000.00